FRATES JAMES M 4

What Happened
James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals (AMLX), reported an open-market sale of 3,557 shares on 2026-02-02. The shares were sold for a weighted-average price of $14.65, generating proceeds of approximately $52,097. This sale was a disposition (sale), not a purchase.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Transaction type: Sale (open market/private sale); total shares sold: 3,557; weighted-average price: $14.65; price range: $14.460–$14.790.
• Reported value: ~$52,097.
• Reason/footnote: Sale was automatic to cover tax withholding related to the vesting of restricted stock units (footnote F1); not at the reporting person's discretion.
• Ownership after transaction: Not specified in this Form 4.
• Additional footnotes: Shares are held in several trusts for which Frates serves as trustee or annuitant; he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest (F3–F5). Full per-price breakdown available to SEC upon request (F2).

Context
This was a routine, non-discretionary sale to satisfy tax withholding obligations on vested RSUs (a common practice), which generally does not signal a change in insider sentiment. No options were exercised and no new awards or purchases were reported in this filing.